CA-BELKIN
25.6.2024 17:01:34 CEST | Business Wire | Press release
Belkin, a leading consumer electronics brand for 40 years, today announced the availability of the BoostCharge Pro Magnetic Power Bank, built with Qi2 wireless charging technology. It is available to order today in 5K and 10K options, and in five fresh new colors – cyber lime, sand, pink, blue, and gold.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625730951/en/
Belkin BoostCharge Pro Magnetic Power Bank 5K in cyber lime, sand, pink, blue and gold color options. (Photo: Business Wire)
Unveiled earlier this year, Belkin’s Qi2 power bank lineup delivers up to 15W of fast charging power for iPhone 12 models and later, without the hassle of cables. They are engineered with an integrated kickstand for propping the phone up while streaming, reading or chatting, and work with magnetic and MagSafe cases up to 3mm thick. They are designed to fit perfectly on the back of iPhone without obstructing camera. “Power pass-through” allows for charging the power bank and attached devices in one simple action via USB-C port.
BoostCharge Pro Magnetic Power Bank 5K
- Fast charges iPhone 12 models and later up to 15W with Qi2 when battery pack is plugged in, and up to 7.5W when used as battery pack
- Provides up to 16 hours of additional battery life1
- Built with 1 x USB-C port to charge two devices simultaneously2
- Packaged with USB-C to USB-C cable to start charging right out of the box
- Available in black, cyber lime, sand, pink, and blue color options; gold available in European markets only
- $59.95 USD
BoostCharge Pro Magnetic Power Bank 10K
- Fast charges iPhone 12 models and later up to 15W with Qi2 (delivers 0-25% charge in 21 minutes3), or up to 20W with integrated USB-C cable
- Provides up to 35 hours of additional battery life4
- Built with 1 x USB-C port and integrated USB-C cable to charge three devices simultaneously5
- Available in black
- $99.95 USD
In line with Belkin’s commitment to build products more responsibly, the BoostCharge Pro Magnetic Power Bank offerings are made with a minimum of 72% post-consumer recycled materials (PCR) and packaged in 100% plastic-free packaging.
Media kit can be found HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
___________
1 Maximum additional video playback hours calculated by comparing the mAh capacity of this power bank with the maximum video playback hours achievable by the iPhone 15 under normal conditions. Actual results will vary depending on differing factors for individual users.
2 When one device is charging: 7.5W wireless or USB-C 12W max output. When two devices are charging: 5W wireless + 5W max USB-C
3 Based on internal tests using iPhone 15; results may vary depending on various conditions.
4 Contains a 10,000 mAh internal battery. Amount of discharge to user’s device is less and may vary depending on various conditions. Maximum additional video playback hours calculated by comparing the capacity of the internal battery of this power bank with the maximum video playback hours achievable by the iPhone 15 under normal conditions. Actual results will vary depending on conditions and use.
5 When one device is charging: 15W wireless, or USB-C 20W max output. When two devices charging: 7.5W wireless + 10W max USB-C. When three devices charging: 15W max shared
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625730951/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom